IDEXX LABORATORIES INC /DE — Director's Dealing 2013

Oct 28, 2013

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2013-10-24

Reporting Person: AYERS JONATHAN W (Director, Chairman, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2013-10-24	Common Stock	M	13000	$25.45	Acquired	352990	Direct
2013-10-24	Common Stock	M	7000	$41.9350	Acquired	359990	Direct
2013-10-24	Common Stock	M	25000	$50.00	Acquired	384990	Direct
2013-10-24	Common Stock	S	38700	$104.1955	Disposed	346290	Direct
2013-10-24	Common Stock	S	389	$104.9694	Disposed	345901	Direct
2013-10-25	Common Stock	M	13000	$25.45	Acquired	358901	Direct
2013-10-25	Common Stock	M	7000	$41.9350	Acquired	365901	Direct
2013-10-25	Common Stock	M	25000	$50.00	Acquired	390901	Direct
2013-10-25	Common Stock	S	8255	$104.2989	Disposed	382646	Direct
2013-10-25	Common Stock	S	30834	$104.5766	Disposed	351812	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2013-10-24	Non-Qualified Stock Option (right to buy)	$25.45	M	13000	Disposed	2014-02-04	Common Stock (13000)	Direct
2013-10-24	Non-Qualifed Stock Option (right to buy)	$41.9350	M	7000	Disposed	2014-02-13	Common Stock (7000)	Direct
2013-10-24	Non-Qualified Stock Option (right to buy)	$50.00	M	25000	Disposed	2014-02-13	Common Stock (25000)	Direct
2013-10-25	Non-Qualified Stock Option (right to buy)	$25.45	M	13000	Disposed	2014-02-04	Common Stock (13000)	Direct
2013-10-25	Non-Qualified Stock Option (right to buy)	$41.9350	M	7000	Disposed	2014-02-13	Common Stock (7000)	Direct
2013-10-25	Non-Qualified Stock Option (right to buy)	$50.00	M	25000	Disposed	2014-02-13	Common Stock (25000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	49000	Indirect

Footnotes

F1: Includes 66 shares, 68 shares and 68 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on 03/29/2013, 06/28/2014 and 09/30/2013, respectively.

F2: The sale reported above was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 02/28/2013.

F3: The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $103.85 to $104.80, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3, 4, 5 and 6 to this Form 4.

F4: The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $104.91 to $105.02, inclusive.

F5: The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $103.48 to $104.475, inclusive.

F6: The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $104.48 to $104.79, inclusive.

F7: Grant of options to buy shares of common stock becomes exercisable as to 22,000 shares on 02/05/2005, 02/05/2006, 02/05/2007 and 02/05/2008, and the remaining 18,072 shares on 02/05/2009.

F8: Grant of options to buy shares of common stock becomes exercisable as to 12,000 shares on 02/14/2008, 02/14/2009, 02/14/2010 and 02/14/2011, and the remaining 9,616 shares on 02/14/2012.

F9: Grant of options to buy shares of common stock that vest in five equal annual installments, beginning on the first anniversary date(02/14/2008) of the date of grant.